Entity

Time filter

Source Type


Wu D.,Fourth Affiliated Hospital of Nantong Medical College | Tao J.,Nanjing Medical University | Ding J.,Nanjing Medical University | Qu P.,Fourth Affiliated Hospital of Nantong Medical College | And 2 more authors.
Molecular Medicine Reports | Year: 2013

Numerous studies have suggested that interleukin 11 (IL-11) has roles in human gastric, prostate and bone cancer and endometrial carcinoma. Hence, we evaluated the expression of IL-11 in bladder cancer and the correlation of IL-11 levels and clinicopathological features. The expression of IL-11 in primary human bladder cell culture, human bladder cancer cell lines, transitional cell carcinoma (TCC) and non-cancerous bladder tissues (NATs) were analyzed by western blotting. Enzyme-linked immunosorbent assay (ELISA) for urinary IL-11 was performed to compare the IL-11 levels in healthy subjects and subjects diagnosed with bladder cancer. Our study suggested that the expression of IL-11 in human bladder cancer cell lines and TCC was down-regulated compared with primary human bladder cell culture and matched NATs. We also demonstrated reduced urinary levels of IL-11 in subjects with bladder cancer compared with healthy subjects. Furthermore, we revealed that the levels of IL-11 were associated with tumor grade and stage. The results suggested that reduced levels of IL-11 may play an important role in the carcinogenesis and progression of TCC. They also indicated that IL-11 may be a promising predictor for prognosis of TCC. Copyright © 2013 Spandidos Publications Ltd.


Zhou Y.,Soochow University of China | Zhou Y.,Fourth Affiliated Hospital of Nantong Medical College | Wu D.,Fourth Affiliated Hospital of Nantong Medical College | Tao J.,Nanjing Medical University | And 3 more authors.
Scandinavian Journal of Urology | Year: 2013

Objective. MicroRNA-133a (miR-133a) and microRNA-133b (miR-133b) are located on chromosome 18 in the same bicistronic unit. Recently, they have been commonly identified as being down-regulated in various human malignancies, such as bladder cancer, pancreatic ductal adenocarcinoma, oesophageal squamous cell carcinoma of the tongue, and hepatocellular and lung carcinomas. The present study examined the effects of miR-133a and miR-133b in bladder cancer T24 and EJ cells. Material and methods. After transfection of miR-133a and miR-133b, the expression of miR-133a/b was assessed, and a cell viability assay, cell migration assay, cell invasion assay, luciferase assay and Western blot were conducted in bladder cancer T24 and EJ cells. Results. Both miR-133a and miR-133b were found to inhibit cell proliferation, migration and invasion in T24 and EJ cells. The first evidence was provided that miR-133a and miR-133b may directly target the epidermal growth factor receptor in bladder cancer. Conclusions. This study provided the first glimpse of the functional role of miR-133 in bladder cancer T24 and EJ cells. The results may increase our knowledge on the molecular basis of progression and provide potential therapy for bladder cancer. © 2013 Informa Healthcare.


Wu D.,Fourth Affiliated Hospital of Nantong Medical College | Niu X.,Fourth Affiliated Hospital of Nantong Medical College | Niu X.,Nanjing Medical University | Pan H.,Fourth Affiliated Hospital of Nantong Medical College | And 4 more authors.
Molecular Medicine Reports | Year: 2016

MicroRNA-497 (miR-497) has been reported to be downregulated in certain types of cancer, including breast, gastric, endometrial, colorectal and prostate cancer as well as hepatocellular and nasopharyngeal carcinoma. The present study aimed to investigate the underlying mechanism of the tumor suppressor function of miR-497 in prostate cancer. Following transfection with miR-497, the DU145 and PC-3 prostate cancer cell lines were subjected to Transwell migration and invasion assays, western blot analysis and a luciferase assay. It was revealed that miRNA-497 inhibited the migration and invasion of prostate cancer cells. In addition, is was indicated that miRNA-497 directly targets hepatoma-derived growth factor (HDGF) in prostate cancer cells. These results suggested that restoration of miR-497 and the resulting downregulation of HDFG may represent a promising therapeutic strategy for prostate cancer.


Wu D.,Fourth Affiliated Hospital of Nantong Medical College | Niu X.,Nanjing Medical University | Pan H.,Fourth Affiliated Hospital of Nantong Medical College | Zhou Y.,Fourth Affiliated Hospital of Nantong Medical College | And 2 more authors.
Molecular Medicine Reports | Year: 2016

The expression of microRNA-335 (miR-335) has been demonstrated to be downregulated in numerous types of cancer. Thus far, no previous studies have investigated the MIR-335 expression in bladder cancer. In the present study, the expression and effects of MIR-335 were assessed in bladder cancer. The results of the present study provided, to the best of our knowledge, the first evidence that MIR-335 is downregulated in the tumor tissue of patients with bladder cancer. Following transfection of MIR-335, MTT, cell migration and invasion, luciferase and western blot assays were conducted in bladder cancer cell lines. The results demonstrated that MIR-335 inhibited cell proliferation, migration and invasion in T24 and EJ cells. In addition, the results suggested that MIR-335 directly targets Rho-associated protein kinase 1 (ROCK1) in bladder cancer. The present study provided a novel therapeutic target, the MIR-335/ROCK1 axis in bladder cancer. The suggested approach will be beneficial in developing an effective treatment against bladder cancer.


Wu D.,Fourth Affiliated Hospital of Nantong Medical College | Zhou Y.,Fourth Affiliated Hospital of Nantong Medical College | Pan H.,Fourth Affiliated Hospital of Nantong Medical College | Qu P.,Fourth Affiliated Hospital of Nantong Medical College | Zhou J.,Fourth Affiliated Hospital of Nantong Medical College
Molecular Medicine Reports | Year: 2015

microRNA99a (miR99a) was reported to be among the most frequently downregulated miRNAs in numerous types of human cancers, including prostate, bladder, hepatocellular and ovarian carcinoma, squamous cell carcinoma of the tongue, squamous cell lung carcinoma as well as childhood adrenocortical tumors. The aim of the present study was to determine the effects of miRNA99a on cell proliferation, colony formation ability, migration and invasion in prostate cancer. Following transfection with miRNA99a, cell viability, colony formation, cell migration and cell invasion assays were performed on prostate cancer cell lines, as well as western blot analysis and luciferase assays. miRNA99a inhibited cell proliferation, colony formation ability, migration and invasion in DU145 and PC3 cells, therefore indicating that miRNA99a may have a tumor suppressive role in prostate cancer. In addition, the present study provided the first evidence that the mechanism of action of miRNA99a may proceed by directly targeting fibroblast growth factor receptor 3 in prostate cancer. In conclusion, the results of the present study suggested that miRNA99a may have potential use as a therapeutic target for the treatment of prostate cancer.

Discover hidden collaborations